{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:48:56Z","timestamp":1787168936984,"version":"build-2736575974"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2005,11,15]],"date-time":"2005-11-15T00:00:00Z","timestamp":1132012800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1007\/s00432-005-0050-z","type":"journal-article","created":{"date-parts":[[2005,11,14]],"date-time":"2005-11-14T07:36:38Z","timestamp":1131953798000},"page":"99-104","source":"Crossref","is-referenced-by-count":59,"title":["Phase-I\/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy"],"prefix":"10.1007","volume":"132","author":[{"given":"T.","family":"Lissitchkov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Arnaudov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Peytchev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kh.","family":"Merkle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,11,15]]},"reference":[{"key":"50_CR1","unstructured":"Aivado M, Becker K, Neise M, Strupp C, Losem C, Haas R (2001) Bedamustine is an efficient and well tolerated option in the palliation of pretreated B-cell chronic lymphatic leukemias (CLL). PROC ASCO, 20, Abstract 1220"},{"issue":"4 Suppl 13","key":"50_CR2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/sonc.2002.34875","volume":"29","author":"M Aivado","year":"2002","unstructured":"Aivado M, Schulte K, Henze L, Burger J, Finke J, Haas R (2002) Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. Semin Oncol 29(4 Suppl 13):19\u201322","journal-title":"Semin Oncol"},{"key":"50_CR3","unstructured":"Bergmann MA, Herold M, Emmerich B, Boenig L, Hallek M (2003) High efficacy and better haematological safety of reduced dose of bendamustine in extendedly pretreated patients with advanced, relapsed or refractory B-CLL: phase I\/II study of the German CLL Study Group. PROC ASCO, 22, Abstract 2371"},{"issue":"4 Suppl 13","key":"50_CR4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1053\/sonc.2002.34878","volume":"29","author":"BD Cheson","year":"2002","unstructured":"Cheson BD (2002) Hematologic malignancies: new developments and future treatments. Semin Oncol 29(4 Suppl 13):33\u201345","journal-title":"Semin Oncol"},{"key":"50_CR5","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","volume":"87","author":"BD Cheson","year":"1996","unstructured":"Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O\u2019Brien S, Rai RK (1996) National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87:4990\u20134997","journal-title":"Blood"},{"issue":"Suppl 3","key":"50_CR6","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/annonc\/10.suppl_3.124","volume":"10","author":"A Heider","year":"1999","unstructured":"Heider A, Gauler T, Niederle N (1999) Efficacy and toxicity of bendamustine in patients with low grade non hodgkin lymphoma. Ann Oncol 10(Suppl 3):124","journal-title":"Ann Oncol"},{"key":"50_CR7","unstructured":"Kanekal S, Crain B, Elliott G, Singh S (2004) SDX-105 (Bendamustine) inhibits growth of SU-DHL-1 and daudi lymphoma xenografts in SCID mice. PROC AACR 45, Abstract 4575"},{"key":"50_CR8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s004320000180","volume":"127","author":"R Kath","year":"2001","unstructured":"Kath R, Blumenstengel K, Fricke HJ, H\u00f6ffken K (2001) Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukaemia. J Cancer Res Clin Oncol 127:48\u201354","journal-title":"J Cancer Res Clin Oncol"},{"key":"50_CR9","unstructured":"Leoni LM, Bailey B, Reifert J (2003) SDX-105 (Bendamustine), a clinically active antineoplastic agent possesses a unique mechanism of action. Blood 102 (11), 640a (Abstract 2363)"},{"key":"50_CR10","unstructured":"Leoni LM, Bailey B, Reifert J, Niemeyer C, Bendall H, Dauffenbach L, Kerfoot C (2004) In vitro and ex vivo activity of SDX-105 (Bendamustine) in drug-resistant lymphoma cells. PROC AACR 45, Abstract 1215"},{"key":"50_CR11","unstructured":"Niemeyer C, Bailey B, Reifert J, Bendall H, Corbeil J, Leoni LM (2004) SDX-105 (Bendamustine) is a clinically active chemotherapeutic agent with a distinct mechanism of action. PROC AACR 45, Abstract 1129"},{"key":"50_CR12","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s007610050267","volume":"4","author":"M Rummel","year":"1998","unstructured":"Rummel M (1998) Diagnostik und Therapie der chronischen lymphatischen Therapie (CLL). Der Onkologe 4:808\u2013819","journal-title":"Der Onkologe"},{"key":"50_CR13","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00001813-199606000-00007","volume":"7","author":"D Strumberg","year":"1996","unstructured":"Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S (1996) Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anti-Cancer Drugs 7:415\u2013421","journal-title":"Anti-Cancer Drugs"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-005-0050-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-005-0050-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-005-0050-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T17:18:25Z","timestamp":1586539105000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-005-0050-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,15]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["50"],"URL":"https:\/\/doi.org\/10.1007\/s00432-005-0050-z","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11,15]]}}}